- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.02. | Data cues up AZ oral SERD filing in first-line breast cancer | ||
| 25.02. | Rishi Sunak becomes prostate cancer ambassador | ||
| 25.02. | Lilly launches discounted high-strength Zepbound vials in US | ||
| 25.02. | Evidence builds behind Regeneron's deafness gene therapy | ||
| 25.02. | AI tool detects brain lesions linked to epilepsy | ||
| 25.02. | Ex-CDER chief Cavazzoni rejoins Pfizer as CMO | ||
| 24.02. | FDA looks at Opdivo/Yervoy in first-line colorectal cancer | ||
| 24.02. | FDA clears first therapy for rare disease CTX from Mirum | ||
| 24.02. | Pfizer drops Beqvez, leaving its gene therapy cupboard bare | ||
| 24.02. | Pfizer drops Beqvez, leaving gene therapy cupboard bare | ||
| 24.02. | Compounders cast adrift after semaglutide shortage ends | ||
| 24.02. | Troubled gene therapy player bluebird sold for a song | ||
| 21.02. | Trial of Boehringer's cystic fibrosis gene therapy imminent | ||
| 21.02. | NICE backs consolidation use of Blincyto in leukaemia | ||
| 21.02. | Poolbeg slumps as Hookipa merger is called off | ||
| 21.02. | AstraZeneca builds in China as Cosette buys Mayne | ||
| 21.02. | Kennedy delays first vaccine expert meeting under his watch | ||
| 20.02. | NICE changes its mind on BMS' lymphoma cell therapy | ||
| 20.02. | Boehringer eyes third quarter FDA verdict for oral HER2 drug | ||
| 20.02. | Pharma lobbies Trump as 25% tariff on imports looms | ||
| 20.02. | SMA treatment with Evrysdi 'could start prenatally' | ||
| 20.02. | UCB's non-cannabis drug for severe epilepsy gets NHS okay | ||
| 19.02. | Biogen bags rights to epilepsy drug from Stoke in $550m deal | ||
| 19.02. | Supernus reports less than super data for depression drug | ||
| 19.02. | FDA sets June date for Gilead's twice-yearly HIV PrEP |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
